Butidrine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Butidrine
Butidrine.svg
Names
IUPAC name
2-(Butan-2-ylamino)-1-(5,6,7,8-tetrahydronaphthalen-2-yl)ethanol
Other names
Butedrine; Butydrine; Hydrobutamine; Idrobutamine
Identifiers
3D model (JSmol)
ChemSpider
Properties
C16H25NO
Molar mass 247.38 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Butidrine (INN) (brand names Betabloc, Butidrate, Recetan), or butedrine or butydrine, also known as hydrobutamine or idrobutamine, is a beta blocker related to pronethalol[1] and propranolol[2] that was developed in the 1960s.[3][4] Similarly to certain other beta blockers, butidrine also possesses local anesthetic properties.[5]

References[edit]

  1. ^ James A. Bristol (1986). Cardiovascular drugs. John Wiley & Sons, Incorporated. p. 111. ISBN 978-0-471-09228-5. 
  2. ^ Drug Metabolism Reviews. Marcel Dekker. 1972. 
  3. ^ I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 58–. ISBN 978-94-011-4439-1. 
  4. ^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 197–. ISBN 978-1-4757-2085-3. 
  5. ^ Robert Charlier (1971). Antianginal drugs: pathophysiological, haemodynamic, methodological, pharmacological, biochemical and clinical basis for their use in human therapeutics. Springer-Verlag. ISBN 978-3-540-05365-1.